JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - LEXICON PHARMACEUTICALS INC
It's my pleasure to have the Lexicon team with me today. To my direct left is Craig Ranowitz, Chief Medical Officer, and to his left is Mike Exton, CEO. Welcome, both of you. Thanks, Andy. As per usual, would you guys mind talking about the Lexacon story, what programs you're working on, indications you're pursuing, and what kind of milestones we can expect? Yeah, sure. So over the last two years, really, we've worked very hard to focus the company into a cardiometabolic company focused on serious cardiometabolic disease. And now we have a range of late-stage and early-stage assets that are really progressing well in the pipeline. So the most prominent of which is Sotocloplozin for hypertrophic cardiomyopathy, which now is in a phase three trial that's fully enrolled with a readout in quarter one of next year. We have the same drug that we're about to resubmit for type one diabetes and with a potential approval in 2027. We have a program that's phase three ready for diabetic peripheral neuropathy that is continuing to build on a number of different indications for AAK1. And at the same time, we have a programme in partnership with Nova Nordisk for LX9851 in obesity and other indications. So really a range of programs that have a number of catalysts moving forward. Perfect. So I wanted to dig in on the big catalyst coming up, the Phase 3 HCM, so not a trial with data in Q1 of next year. Big picture, if this did work in HCM broadly, obstructive and non-obstructively, how would this be positioned relative to other current drugs in the marketplace? Yeah, so the approach we've taken over the last couple of years is we've called it Lead to Succeed, which is really positioning us in places where we are the one and only indication in mechanism. And this is playing out in HCM in particular because it allows us to be the only mechanism, the only drug in that mechanism and so we think that with a oral once daily oral medicine that's safe and very tolerable that we could play a broad or have broad applicability across patients and prescribers in HCM that's allows it to be used as a monotherapy or in combination with the current CMIs and and presumably no black box unlike the cmy's for instance this is a very safe and very tolerable medicine so having that and it should work out and show to be effective in hcm we think that it really is a Very easy medicine to use and patients will see the benefits of having a once daily medicine, oral medicine, that really is effective, but at the same time highly tolerable. And as we dig into why you're confident, why you feel confident, maybe the natural question could be why haven't other SGLT inhibitors pursued HCM, or maybe they have, but why are you different here? Yeah. Craig, you want to take that? Yeah. Thank you, Andrew, for the question. I think some of it was the insight we had based on looking at our large heart failure program, which, again, had defining characteristics that were not seen in the heart failure programs of the SGLT2 inhibitors, particularly the benefits that we have regardless of ejection fraction, where the SglT2 in inhibitors at normal ejection fraction lose their relative effectiveness, and pseudoglyphosin maintain that effectiveness throughout the range of ejection faction. As you know, patients with HCM, by and large, have normal or hypernormal ejection fraction. The second area that we've identified is that SOTA and SGLT1 receptors are expressed on the myocardium, and S GLT2 receptors are not expressed on the myo-cardium. Standard heart failure, for which the SGL T2 inhibitors and SOTO glyphosate are approved, is largely a cardiorenal phenomenon, not a direct cardiac phenomenon. And having SGLT1 receptors and not SGL2 receptors directly on the myocardium is a meaningful differentiator. We know that SGL1 is increased in expression in cardiac disease states, including HCM. The third area that we feel confident about is the effects on thromboembolic events, and we've now mechanistically disentangled that, including publications as recently as the last couple months that show there is a decrease with sodaglifosin, the dual inhibitor, but not empaglificosin which is an STLT2-specific inhibitor on platelet degranulation, inflammatory markers, and others and that there is reduction in thrombosis formation with soda but not with empa. And as you know that patients with HCM have very high rates of AFib, large left atria, and over time are at much higher risk of thromboembolic events. So when you put all of that together, we have all the cardio-renal benefits, where you're going to have traditionally with heart failure, no matter what its cause, of fluid overload. We know that you are reducing glucose. Many of these patients have either diabetes or are at risk of diabetes. You reduce blood pressure. You increase hematocrit. So you have all of those effects. You have direct myocardial effects, and then you also have effects on thromboembolic events. And we know that we have effects that SGLT2 inhibitors don't have in patients with normal ejection fraction. Thanks. But I think, Andrew, it's important to emphasize that, that these pleiotropic effects of sotagliflozin are really going to have a significant impact on HCM because it's a very complex disease that manifests itself in a range of ways and having multiple targets, multiple mechanisms by which it can improve HCM is going to be very important for the class going forward. And what's unique about your program I feel has been that this trial combines both obstructive and non-obstructive together. The first question would be, I imagine the press release comes in Q1, you could go a lot of ways to dissect the data in the subgroup. So how detailed is that data set could we expect in Q1 and how much are you saving instead for a medical conference? Look, I think the most important is to show the top line obviously, which is the primary endpoint of case CQ change across both obstructive and non-obstructive for the collective group. We'll certainly provide that then subsequently most and safety will will provide some detail there but most of the the rest of secondary endpoints etc would save for a medical meeting we think sounds good and speaking of the collective group what kind of placebo-adjusted efficacy Delta have you assumed on KCCQ and your Yeah, I mean, we used the insights from the myosin inhibitors to think about how to ways to power the study. Plus, we have all the experience we have in more than 12,000 patients in two heart failure studies that led to the registration of MPEFA in heart failure. So on that basis, we really powered something, and again, a discussion with both the FDA and our clinical experts, of about a five-point difference in KCCQ score with a similar variance around the point estimate difference of placebo-adjusted KCCQ increase at week 24. Male Speaker 1 Okay. And then for the other CMIs specifically like Bristol's drug, cytokinetics drug, what did they show in obstructive and nonobstructive on KCCU? Dr. So, you know, this is a great question, Andrew, because I think this is one where a lot of analysts and others that we talk to are projecting the effect size by subgroup from the CMIs onto soda. And as Mike already mentioned, the sarcomeric drugs are acting in a very different way than soda. One of the insights and advantages of soda is it's acting in manner that is independent of whether they have obstructive or nonobstructive disease because the major impact directly on the myocardium is on diastole. The common fundamental issue in patients with HCM is they have impaired relaxation in diastole. I mean, there are other more subtle differences, particularly the obstructive group tends to be more hyperdynamic when the CMIs are used as opposed to later in the disease where they're not quite as hyperdynamic. But the major issue, the major myocardial dysfunction is early diastolic relaxation of the left ventricle. And by acting directly on that, we assume the effect size is going to be similar across the two groups. And it is important to note that unlike what the CMIs have shown, we have a similar KCCQ score at baseline, whether they have obstructive or non-obstructive disease. Both are in the upper 50s, and there were differences. And, again, it's very hard to project based on only four studies of what is consistent with a KCCq score for baseline. And cross-trial comparison is always difficult. But the fact that we have a similar baseline KCCQ in both the obstructive and non-obstructive in our trial and we're powered for the overall endpoint of obstructive and nonobstructive is, again, another factor that makes us feel comfortable that we picked the right design. I think, Craig, it's important to note here that, you know, clearly the myosin inhibitors are effective in obstructive disease. The KCCU change there is notable. In non-obstructive disease, it's pretty small. That's right. So here, as Craig mentioned, we expect a common KCQ improvement across both obstructive and non- obstructive disease. And significantly, the unmet need is huge in non-ostructive HCM. And here, with the myosin inhibitors, the KCQ improvement is modest and reversible once you discontinue the drug. And if we see an improvement in non-obstructive disease in particular, where the diagnosis rate is continuing to grow, where the unmet need is significant we see a real opportunity for soda to become a first choice of new medicines in that class make sense I mean made to be clear you know cytokinex has all only positive non obstructive data and they showed it like a three-point placebo-adjusted change and you're hoping for five that's not different between the two subgroups so right and Not that you have to beat them. We need to also keep in mind that the efficacy is one part, but, of course, the safety and tolerability is another part, and the logistics involved in prescribing these medicines is important. And if we see a positive result from Sonata in non-obstructive with, as we mentioned, a very safe and tolerable medicine, then it really offers a very good benefit-risk profile. I think related to Mike's point, Andrew, because I think this is a really important element, is barriers to entry and representativeness of the population in your clinical study. And we had far more or far less restrictive entry criteria into the trial, whether you look at BNP, you look at ejection fraction, you Look at underlying medications. This really meets, I think, one of the feedbacks we've had from the medical community since we released the baseline characteristics, as I said, this is my population, because allowing ejection fraction down to 50%, not limiting it to patients with very high baseline BMPs, not limiting to those not on any of the underlying medications, including a CMI, this is representative of their population. And despite the fact of having a much broader range of patients, we still had a highly symptomatic group that warrants and needs therapy and um you've enrolled is it 542 542 what is that next patient mix between obstructive and non-obstructed and did that surprise you by it so the the mix was 440 in the non obstructive group in 102 in the obstructive Group and remember that also includes about 40 patients that are on a CMI, so one of the sub-analyses will obviously be taking all those CMI patients who had obstructive disease when they were first put on a CMI long before they're enrolled in the trial. And only less than half of those were obstructive that were in the trials. So the patients that were on CMIs, both at entry into Sonata, had obstrative disease and non-obstructive disease, regardless were symptomatic. We got feedback early on from our steering committee is don't Don't cap enrollment. Take what comes because that's going to be the power of your medication with its ease of use to say this is the population in the clinics. By capping it, you're going to, in a sense, hamper its applicability because you're gonna put limitations on that. So while the 80-20, I think when people first look at it, they say, gee, is that surprising? To Mike's point, the majority of patients being identified now are more non-obstructive than obstructive. And there is therapy available for obstructive disease. But let's double-click on that, Craig, because nearly 10% of the patients were on a CMI. And that's clearly a great data set because we'll see what is the efficacy and safety, although it's obviously not powered to show any differences or effects, but we'll see that in some analyses. But it shows that there's still, despite using a myosin inhibitor, there's Still significant symptomology amongst these patients. And so having something that directly affects diastole, like soda does, is important, both for obstructive and non-obstructive disease. Very clear. And speaking of the baselines you mentioned earlier, You shared the baseline values of the KCCQ scores by subgroup at a conference, I think, a couple weeks ago or so. I found it notable that the baseline KCCq scores for your trial were relatively lower than the CMI's, suggesting a greater symptom burden at baseline. Is that a good thing in terms of maximizing the chances of success in your study? I think the simple answer is yes. And the reason why is that as you get more and more normalized KCCQ, less and less symptom burden, the ability to demonstrate a benefit also shrinks because if the patients have nearly normal function, then normalizing something that's almost already normal, you're not going to have as large of a benefit. It's sort of a we face this, and, Andrew, I know we've talked about this in the past, is the PRO scores with neuropathic pain as well, is that when you have patients that don't have much baseline symptom, the ability to demonstrate a benefit with your therapy is also compromised. Right. And, oh, yeah, in placebo behavior between the two subgroups, any insight on generally speaking how placebo trends are? Is placebo similar on KCCQ? Yeah, so this is another really good question, and we've had this question before, and we're really gone back and checked our assumptions and talked to our experts and our steering committee, and there's no biological basis to think the placebo effect is going to be different in those with obstructive or non-obstructive disease. Again, I think people are deeply interpreting results from a very limited set of studies. Again, there's four studies that have been done. That's it. And I think it's very hard to project that and say that this is what it is. There's no biological basis to say why patients with obstructive disease would have a different placebo response than those with non-obstructive disease. Yeah, Andrew, we're very confident in the study design and execution here because there are two variables that are going to impact the likelihood of a significant result. the effect size, obviously, which we've talked about, the difference in case CQ, but also the variability in the trial. And here we've modelled it and powered it based on the myosin inhibitor variability. But at the same time, we have a drug that's very tolerable, very safe. We don't know the data yet, but the likelihood of having dropouts and dosage changes is smaller, we would expect, than what you see with the myosin inhibitors. So you put together both our confidence in the ability to show a significant difference and a low variability of the data gives us a lot of confidence in the possibility of success of the trial. Okay. So the trial reads out in Q1, you file later, it could be approved in 2028. Right. And then is this something you'd be inclined to market yourselves? Yes, absolutely. Okay. This is, you know, we've worked very hard as a management team to focus the company and to look at where we can really commercialize medicines ourselves. And HCM is that one space where we feel we have the capabilities and the market opportunity is large enough that we'll market that ourselves, while at the same time looking to partner some of our other programs where we feels we can do that better together, essentially. And we're talking about Sotagliflozin, which is actually already approved in heart failure. Do you plan to have a pricing differential in HCM, and how do you go about it? The short answer is yes. And really, we've already taken this approach in type 1 diabetes, where we've got a new NDA for type 1 disease, a new drug name, a New NDC. It's called Zynquista, and we will take the same approach with HCM. So they're two very different diseases, and the value that the medicine can bring should be reflected in the price that we can charge for HCM I see. And then maybe shifting to Zynqista for type 1 diabetes, you could be refiling to the FDA in first quarter of 2027, is that correct? Correct. But long story short, my understanding is the FDA wanted to see some additional safety data, which you've been able to leverage from a third-party study specifically on DKA safety rates. And so what is the conclusion of that safety database that you saw exactly? Yeah, let me comment, and then, Craig, you also pile on here. So, you know, the FDA for a number of years has been convinced in the efficacy of the drug in type 1 diabetes, which is important because it has the potential to be the first and only adjunct to insulin. Remember, in type 2 diabetes, there are a numberof medicines approved for the control ofglycemia, but in type1 diabetes, it's insulin. That's it. And they've been convincedin the efficacy for a number of years, but they've had some concerns around the rates of diabetic ketoacidosis, which is a phenomenon in type 1 diabetes anyway, and they believe that soda increased the rate of DKA. And as you mentioned, we're able to leverage a third-party study because they wanted new prospective data. That's really what they wanted, to be able to feel comfortable that the rates of DKA were acceptable with soda. Now we've been able to leverage this third-party study, and what we've seen actually is that the rights of DKI are the same with soda as they are with the standard of care, and that that rate is much lower than what we saw in the in tandem phase three program. And we know that because it's an open-label study. We see the data in real time. And so really, for the first time in a number of years, we've agreed with the FDA what we need to demonstrate. We believe that we have now fulfilled those criteria that the FDA set out. And Craig and his team are busy preparing the file to resubmit. And again, like HCM, this is an indication for which SOTA would be the first and only in its class. and that affords us a very significant commercial opportunity. And so specifically, I think the tandem DKA rates, is it 3.5 cases per 100 patient years? Your point is you saw something lower. Yeah, so it took a long time to get the FDA to actually be specific in what they were looking for. After a long series of discussions with the FDA, we aligned on the following criteria. They wanted to see an exposure number of years, number of patient years, similar to the entire in tandem program, which was the largest glycemia program done for registration with the FDA. And it was about 200 patient years. At least 200 patient of exposure. And then the second criteria is a rate of DKA that was less than that seen in the in tandem program. And Andrew, as you pointed out, it's about three and a half cases of diabetic ketoacidosis per 100 patient years. And the data that we shared at our most recent earnings call, which was the data as of the end of August in the Stena 1 program, achieved both of those hurdles. We had an exposure at that point, and again, that trial continues to enroll, and we expect to continue to update that data with the FDA during the review and then thereafter. But we achieved that overall exposure level of 200 patient years, and the rate of DKA, as we shared, was about roughly one per 100 patient years, which is both similar to the untreated control in that study and way below the rate that was observed in the in tandem program. Great to hear. And then maybe final question is, you could have two approved products launching in 2028. What is the patent life of Sotagliflozin? Remind me. Yeah, so we have composition of matter PTE out to 2033. We have a suite of secondary patents, method of use, formulation patents that extend well into the 2040s and we continue to build on that. Thank you so much for the updates and best of luck to the HCM Data Reda and Type 1 Diabetes refiling. Appreciate it Andrew. Thanks so much. Thank you everyone for listening. Cheers. Thank you.
- Company
- LEXICON PHARMACEUTICALS INC
- Keywords
- LEXICON PHARMACEUTICALS INC